Equities analysts forecast that Radius Health Inc (NASDAQ:RDUS) will report $45.67 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Radius Health’s earnings, with the lowest sales estimate coming in at $45.00 million and the highest estimate coming in at $46.06 million. Radius Health reported sales of $27.64 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 65.2%. The firm is expected to report its next earnings results on Thursday, November 7th.

On average, analysts expect that Radius Health will report full year sales of $168.65 million for the current year, with estimates ranging from $167.47 million to $170.07 million. For the next financial year, analysts expect that the company will post sales of $231.93 million, with estimates ranging from $205.71 million to $243.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Radius Health.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.09. Radius Health had a negative net margin of 127.22% and a negative return on equity of 368.58%. The company had revenue of $41.04 million during the quarter, compared to analyst estimates of $40.60 million. During the same period in the prior year, the business posted ($0.99) earnings per share. Radius Health’s revenue for the quarter was up 81.4% on a year-over-year basis.

A number of equities analysts recently issued reports on the stock. Citigroup raised shares of Radius Health from a “neutral” rating to a “buy” rating and increased their price target for the stock from $24.00 to $40.00 in a research note on Thursday, August 29th. Cowen reissued a “hold” rating on shares of Radius Health in a research note on Thursday, August 8th. BidaskClub downgraded shares of Radius Health from a “buy” rating to a “hold” rating in a research note on Thursday, October 3rd. Morgan Stanley assumed coverage on shares of Radius Health in a research note on Thursday, September 5th. They issued a “buy” rating and a $43.00 price target for the company. Finally, ValuEngine downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $36.50.

RDUS stock traded up $0.25 during trading on Friday, reaching $23.81. The company had a trading volume of 99,110 shares, compared to its average volume of 559,415. Radius Health has a 52 week low of $12.81 and a 52 week high of $29.97. The company has a market cap of $1.09 billion, a P/E ratio of -4.88 and a beta of 0.78. The business has a 50 day moving average of $26.58 and a 200 day moving average of $23.08. The company has a debt-to-equity ratio of 6.75, a current ratio of 4.38 and a quick ratio of 4.28.

Several hedge funds and other institutional investors have recently made changes to their positions in RDUS. Meeder Asset Management Inc. purchased a new position in shares of Radius Health during the 2nd quarter valued at $34,000. Captrust Financial Advisors acquired a new position in Radius Health during the 2nd quarter valued at approximately $38,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Radius Health by 3,130.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,423 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 2,348 shares in the last quarter. Quantamental Technologies LLC acquired a new position in Radius Health during the 2nd quarter valued at approximately $62,000. Finally, SG Americas Securities LLC acquired a new position in Radius Health during the 1st quarter valued at approximately $157,000.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Featured Story: What is a price target?

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.